PMA device
Barostim System
Cvrx, Inc. · Stimulator, Carotid Sinus Nerve (DSR, Class III) · First FDA decision Apr 12, 2022, newest Dec 22, 2023Heart failureHigh blood pressure (hypertension)
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
20
Naming "Barostim"
MAUDE reports
440
Brand "Barostim", since 2015
PubMed studies
38
Mentioning "Barostim"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Barostim System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- Barostim SystemPMA supplement
P180050-S009 · Decided Dec 22, 2023 · 198 days after receipt · Normal 180 Day Track
Device type: Stimulator, carotid sinus nerve (DSR) · Cardiology
- Barostim SystemPMA supplement
P180050-S007 · Decided Jun 27, 2022 · 27 days after receipt · Normal 180 Day Track No User Fee
Device type: Stimulator, carotid sinus nerve (DSR) · Cardiology
- Barostim SystemPMA supplement
P180050-S006 · Decided Jun 14, 2022 · 25 days after receipt · Normal 180 Day Track No User Fee
Device type: Stimulator, carotid sinus nerve (DSR) · Cardiology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Phrenic Nerve StimulatorNational determinationOn the books160.19Updated Jun 12, 2020
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Barostim", any status and sponsor, newest update first.
- Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart FailurePivotal-lookingRecruiting
CVRx, Inc.Not on our public-company list
NCT07232030 · 2,500 participants (planned) · Start Apr 24, 2026 · Primary completion Jan 2033
Device: Barostim System · For: Heart Failure; Heart Failure NYHA Class II; Heart Failure NYHA Class III
Sites: Mobile, Alabama; Los Angeles, California; Clearwater, Florida · 26 sites in all
- BATwire Implant Kit StudyTerminated
CVRx, Inc.Not on our public-company list
NCT04600791 · 93 participants · Start Jan 29, 2021 · Primary completion Aug 28, 2024
Device: BATwire Implant Kit · For: Heart Failure
Sites: Mesa, Arizona; Scottsdale, Arizona; Orlando, Florida · 10 sites in all
- Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)Terminated
CVRx, Inc.Not on our public-company list
NCT04502316 · 435 participants · Start Jun 26, 2020 · Primary completion May 14, 2026
Device: Barostim™ System · For: Heart Failure
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 46 sites in all
17 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Barostim", and for the whole product code for context.
This brand
440 reports: 3 malfunction, 406 injury, 31 death
Whole product code DSR
451 reports: 4 malfunction, 416 injury, 31 death
Newest reports for this brand
- Barostim Neo2Injury
3007972010-2026-00125 · Received Oct 29, 2026 · Event dated Sep 27, 2026
Device type: Stimulator, Carotid Sinus Nerve (DSR)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Unspecified Infection; Pain; Swelling/ Edema
- Barostim Neo2Injury
3007972010-2026-00123 · Received Oct 28, 2026 · Event dated Sep 29, 2026
Device type: Stimulator, Carotid Sinus Nerve (DSR)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Pain
- Barostim Neo2Injury
3007972010-2026-00124 · Received Oct 28, 2026 · Event dated Sep 30, 2026
Device type: Stimulator, Carotid Sinus Nerve (DSR)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Fever; Swelling/ Edema; Medical device site infection
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Barostim"[tiab]. The summary above synthesizes these.
- Implant-Mediated Therapy of Arterial Hypertension.
Gierthmuehlen M, Plachta DTT, Zentner J · Curr Hypertens Rep · 2020Review
- Electrical carotid baroreceptor stimulation.
Schmidli J, von Allmen RS, Mohaupt MG · Wien Med Wochenschr · 2014
- [Resistant hypertension and carotid baroreceptors stimulation].
Lantelme P, Harbaoui B, Courand PY · Presse Med · 2015English Abstract, Review
- Baroreceptor Stimulation for Resistant Hypertension.
Yoruk A, Bisognano JD, Gassler JP · Am J Hypertens · 2016Review
- Baroreceptor stimulation in a patient with preexisting subcutaneous implantable cardioverter defibrillator.
Weipert KF, Andrick J, Chasan R, et al. · Pacing Clin Electrophysiol · 2018Case Reports
- Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertension.
Wallbach M, Böhning E, Lehnig LY, et al. · J Hypertens · 2018
- Old problem surfaces with new technology: Twiddler's syndrome in Barostim NEO.
Rao A, Rao L, Parekh A, et al. · J Cardiovasc Imaging · 2024
- Antiarrhythmic effects of baroreceptor activation therapy in chronic heart failure: a case report.
Wang D, Veltmann C, Bauersachs J, et al. · Eur Heart J Case Rep · 2023Case Reports
- Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience.
Blanco C, Madej T, Mangner N, et al. · ESC Heart Fail · 2023
- InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
Soto M, Sampietro-Colom L, Sagarra J, et al. · Rev Esp Cardiol (Engl Ed) · 2016
- Baroreflex Amplification and Carotid Body Modulation for the Treatment of Resistant Hypertension.
Groenland EH, Spiering W · Curr Hypertens Rep · 2020Review
Other devices of this type
Also filed under product code DSR.
- BAROSTIM NEO® SystemCvrx, Inc. · PMA 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.